Bad actors are using online ads, social media and bootleg ingredients to sell fake, inaccurate and harmful versions of these ...

Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Millions of Americans rely on a new class of medications to manage chronic conditions like diabetes and obesity, with ...

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.

礼来是全球最有价值的医疗保健股票，市值超过8000亿美元。在过去12个月里，股价上涨了超过50%。尽管增长前景强劲，但投资者可能会对该股超过100倍的市盈率感到犹豫。

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.